Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegsunercept

Next Previous
Drug Profile

Pegsunercept

Alternative Names: PEG sTNF-R1; PEG sTNF-RI; Pegylated recombinant methionyl human soluble tumour necrosis factor receptor type 1; Pegylated soluble tumour necrosis factor receptor type I

Latest Information Update: 23 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 03 Aug 2006 No development reported - Phase-II for Rheumatoid arthritis (unspecified route)
  • 03 Aug 2006 No development reported - Phase-II for Rheumatoid arthritis in USA (unspecified route)
  • 31 Dec 2003 Amgen has completed a Phase-II trial in Rheumatoid arthritis in the USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top